Intravenous Treatment with Gammaglobulin in Adults with Immune Thrombocytopenic Purpura: Review of the Literature<sup>1</sup>

DOI Web Site Web Site 被引用文献2件

書誌事項

公開日
1987-04
権利情報
  • http://onlinelibrary.wiley.com/termsAndConditions#vor
DOI
  • 10.1111/j.1423-0410.1987.tb03029.x
公開者
Wiley

この論文をさがす

説明

<jats:p><jats:bold>Abstract. </jats:bold> The results of high‐dose intravenous gammaglobulin therapy (IVGG) of adults with immune thrombocytopenic purpura (ITP) were reviewed in 28 published reports which included 282 patients. Overall, 64% of the patients responded to IVGG with a peak platelet count greater than 100,000/mm<jats:sup>3</jats:sup>; 83% had peak platelet counts greater than 50,000/mm<jats:sup>3</jats:sup>. Unmodified immunoglobulin was superior to modified immunoglobulin; 70% of the patients treated with the former having platelet increases to >100,000/mm<jats:sup>3</jats:sup> compared to only 49% of those treated with the latter. More patients were refractory among those who had had ITP for at least 3 years. A higher peak platelet count immediately after IVGG administration was correlated with a longer duration of the platelet response. Patients above the age of 60 tended to have a weaker response to IVGG than did younger patients, and females tended to respond better than males. A pre‐IVGG platelet count of >10,000/mm<jats:sup>3</jats:sup> was <jats:italic>not</jats:italic> associated with a poor response to IVGG. While there is still no way to reliably predict response prior to therapy in an individual patient, the above information may help in the decision of whether or not treatment with IVGG is likely to be successful. It also suggests that inhibition of antiplatelet antibody production is an important mechanism of IVGG effect at least in some patients.</jats:p>

収録刊行物

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ